NLTX - Neoleukin Therapeutics Inc.'s (NLTX) CEO Jonathan Drachman on Q4 2020 Results - Earnings Call Transcript

Neoleukin Therapeutics, Inc. (NLTX) Q4 2020 Earnings Conference Call March 25, 2021, 04:30 PM ET Company Participants Julie Rathbun - Communications Jonathan Drachman - Chief Executive Officer Robert Ho - Chief Financial Officer Daniel-Adriano Silva - Head of Research Carl Walkey - Senior Vice President of Corporate Development Umut Ulge - Vice President of Clinical Development Conference Call Participants Tyler Van Buren - Piper Sandler Arlinda Lee - Canaccord Genuity Presentation Operator Good morning and thank you for joining us today for the Neoleukin Therapeutics Conference Call. At this time, all participants are in a listen-only mode. Following the conclusion of the prepared remarks, we will conduct a question-and-answer session and instructions will follow at that time. As a reminder, today's conference call is being recorded. I would now like to turn the call over to Julie Rathbun, Communications for Neoleukin Therapeutics. Julie, please go ahead. Julie Rathbun Thank you.

For further details see:

Neoleukin Therapeutics, Inc.'s (NLTX) CEO Jonathan Drachman on Q4 2020 Results - Earnings Call Transcript